8-K: Healthcare Giant Revises Full-Year Earnings Outlook Amid Rising Costs

A major health insurer reported increased second-quarter revenue but revised its full-year adjusted diluted EPS guidance downward due to elevated medical cost trends in ACA and Medicaid.

Summary

• Operating revenue for the second quarter of 2025 was $49.4 billion, marking a 14.3% increase from the second quarter of 2024.
• Diluted EPS for the second quarter of 2025 was $7.72, while adjusted diluted EPS was $8.84.
• Full-year 2025 adjusted diluted EPS guidance has been revised to approximately $30.00.
• The company returned $2.0 billion of capital to shareholders year-to-date.
• The benefit expense ratio increased by 260 basis points year over year to 88.9%, primarily due to higher medical cost trends in Medicaid and ACA health plans.
• The operating expense ratio improved by 160 basis points to 10.1%, driven by expense leverage and ongoing discipline.
• Operating cash flow year-to-date was $3.1 billion, an increase of $0.6 billion year over year, representing 0.8 times GAAP net income.
• Medical membership totaled approximately 45.6 million as of June 30, 2025, a decline of 212 thousand from the first quarter of 2025, mainly due to lower Medicaid membership and attrition in Individual ACA business.
• The Health Benefits segment's operating revenue grew by 12% to $41.6 billion.
• The Carelon segment's operating revenue increased by 36% to $18.1 billion, with operating gain up 33% to $0.9 billion.

Sentiment

Score: 4

Explanation: While the company demonstrated strong revenue growth and improved expense management, the significant downward revision of its full-year EPS guidance due to elevated medical costs and membership attrition in key segments indicates a challenging operational environment and a negative adjustment to its outlook. This mixed performance suggests caution.

Positives

• Operating revenue increased by 14.3% to $49.4 billion in the second quarter of 2025, demonstrating strong top-line growth.
• The operating expense ratio improved by 160 basis points to 10.1%, reflecting effective expense management and leverage from revenue growth.
• Operating cash flow increased by $0.6 billion year-over-year to $3.1 billion year-to-date, indicating healthy cash generation.
• The company returned $2.0 billion of capital to shareholders year-to-date, including $379 million in share repurchases and $385 million in dividends during the second quarter.
• Growth in Medicare Advantage membership increased by 11.0%.
• The Carelon segment showed robust growth, with operating revenue up 36% to $18.1 billion and operating gain increasing by 33% to $0.9 billion, driven by acquisitions and scaling of innovative capabilities.
• Approximately $8.0 billion of Board approved share repurchase authorization remains available.

Negatives

• Full-year 2025 adjusted diluted EPS guidance was revised downward to approximately $30.00.
• The benefit expense ratio increased by 260 basis points year over year to 88.9%, reflecting higher medical cost trends, particularly in Medicaid and ACA health plans.
• Medical membership declined by 212 thousand from the first quarter of 2025, primarily due to lower Medicaid membership and attrition in the Individual ACA business.
• Operating gain decreased by 12.3% to $2.4 billion in the second quarter of 2025 compared to the prior year quarter.
• Shareholders' net income decreased by 24.2% to $1.743 billion in the second quarter of 2025 compared to the prior year quarter.
• Diluted EPS decreased by 21.6% to $7.72 in the second quarter of 2025 compared to the prior year quarter.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment.
• Ability to secure and implement sufficient premium rates.
• Impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes.
• Impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application.
• Impact of cyber-attacks or other privacy or data security incidents or failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto.
• Failure to effectively maintain and modernize information systems, or failure of information systems or technology, including artificial intelligence, to operate as intended.
• Failure to effectively maintain the availability and integrity of data.
• Changes in economic and market conditions, as well as regulations that may negatively affect liquidity and investment portfolios.
• Competitive pressures and ability to adapt to changes in the industry and develop and implement strategic growth opportunities.
• Risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon.
• Ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein.
• Negative change in healthcare product mix.
• Costs and other liabilities associated with litigation, government investigations, audits or reviews.
• Ability to contract with providers on cost-effective and competitive terms.
• Risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between the company and CaremarkPCS Health, L.L.C.
• Effects of any negative publicity related to the health benefits industry in general or the company in particular.
• Risks associated with mergers, acquisitions, joint ventures and strategic alliances.
• Possible impairment of the value of intangible assets if future results do not adequately support goodwill and other intangible assets.
• Possible restrictions in the payment of dividends from subsidiaries and increases in required minimum levels of capital.
• Ability to repurchase shares of common stock and pay dividends on common stock due to the adequacy of cash flow and earnings and other considerations.
• Potential negative effect from substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact access to or further increase the cost of financing.
• Downgrade in financial strength ratings.
• Events that may negatively affect licenses with the Blue Cross and Blue Shield Association.
• Intense competition to attract and retain employees.
• Risks associated with international operations.
• Various laws and provisions in governing documents that may prevent or discourage takeovers and business combinations.

Future Outlook

The company revised its full-year 2025 adjusted diluted EPS guidance to approximately $30.00, reflecting the ongoing and industry-wide impact of elevated medical cost trends in ACA and slower rate alignment in Medicaid. Despite these challenges, the company remains focused on managing healthcare costs, deploying targeted investments in advanced technology and value-based care delivery, and reinforcing its operational foundation. Management expressed confidence in achieving at least 12% average annual growth in adjusted diluted EPS over time, leveraging the embedded earnings power of its diversified Health Benefits and Carelon businesses.

Management Comments

• "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system." Gail K. Boudreaux, President and Chief Executive Officer
• "We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid." Gail K. Boudreaux, President and Chief Executive Officer
• "While the external environment continues to evolve, we are focused on the areas within our control managing healthcare costs, deploying targeted investments in advanced technology and value-based care delivery, and reinforcing the operational foundation that supports long-term value creation." Gail K. Boudreaux, President and Chief Executive Officer
• "With the embedded earnings power of our diversified Health Benefits and Carelon businesses, we remain confident in achieving at least 12% average annual growth in adjusted diluted EPS over time." Gail K. Boudreaux, President and Chief Executive Officer

Industry Context

The company's revised outlook explicitly acknowledges that the elevated medical cost trends in ACA and Medicaid, which are impacting its financial performance, are an "ongoing and industry-wide impact." This indicates that the challenges faced are not unique to the company but reflect broader pressures within the healthcare and insurance sectors concerning rising medical expenses and the pace of rate adjustments in government-sponsored programs.

Corporate Governance

Legal Proceedings

• Risks include costs and other liabilities associated with litigation, government investigations, audits or reviews.
• Risks include medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between the company and CaremarkPCS Health, L.L.C.
• Risks include cyber-attacks or other privacy or data security incidents or failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto.

Stakeholder Impact

• Shareholders are impacted by the revised full-year EPS guidance, the ongoing share repurchase program, and the declared quarterly dividend.
• Customers/Members may be impacted by trends in healthcare costs and utilization rates, and changes in premium rates.
• Employees face intense competition for talent, as noted in the risks.
• Healthcare providers are impacted by the company's ability to contract on cost-effective and competitive terms.

Next Steps

• Management will host a conference call and webcast on July 17, 2025, to discuss the second quarter results and outlook.
• A third quarter 2025 dividend of $1.71 per share is payable on September 25, 2025, to shareholders of record on September 10, 2025.

Key Dates

Recommendation

Keywords

Healthcare, Health Insurance, Managed Care, Health Benefits, Pharmacy Services, Carelon, Medicare, Medicaid, ACA, Financial Results, Earnings, SEC Filing, Q2 2025, Guidance, Medical Costs, Membership